The DOI matches its Crossref record; 5 of the 6 references it cites were found in a registry or an index; none of the 2 sources its claims cite is checked for support yet.
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Open accessAbstract
Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months ...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 2 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 109 days (95% CI, 92 to 136) calculated with the use of a power-law model (at day 119)”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 66 days (95% CI, 59 to 72) and 182 days (95% CI, 153 to 254) for live-virus neutralization.”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated half-life of binding antibodies after day 43 for all the participants was 52 days (95% CI, 46 to 58) calculated with the use of an exponential decay model”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with 50% inhibitory dilution (ID50) GMTs of 80 (95% CI, 40 to 135), 57 (95% CI, 30 to 106), and 59 (95% CI, 29 to 121), respectively.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“49,373 (95% CI, 25,171 to 96,849) in those 71 years of age or older.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As measured by ΔAICc (change in Akaike information criterion, corrected for small sample size), the best fit for binding and neutralization were the power-law and exponential decay models, respectively”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The exponential decay model assumes a constant antibody decay rate over time.
- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“62,424 (95% CI, 36,765 to 105,990) in those 56 to 70 years of age”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The neutralizing antibody half-life estimates in the two models were 69 days (95% CI, 61 to 76) and 173 days (95% CI, 144 to 225) for pseudovirus neutralization”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- The authors state this as an assumption: The power-law model assumes that antibody decay rates decrease over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these GMTs were lower in participants 56 to 70 years of age (P=0.03) and in those 71 years of age or older (P=0.005) than in those 18 to 55 years of age”
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 2
In the paper
“Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).1”
What the sources say
- Not checked yetcites [1] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403- 416. 33378609 PMC7787219 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“These results are consistent with published observations of convalescent patients with Covid-19 through 8 months after symptom onset.5”
What the sources say
- Not checked yetcites [5] Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063- eabf4063. 33408181 PMC7919858 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The durability of protection from the mRNA-1273 vaccine is currently unknown.
“The durability of protection is currently unknown.”
The authors state this as an assumption.
The exponential decay model assumes a constant antibody decay rate over time.
“which assumes a steady decay rate over time”
The authors state this as an assumption.
The power-law model assumes that antibody decay rates decrease over time.
“which assumes that decay rates decrease over time”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Current evidence suggests that circulating antibodies persist for at least 6 months postvaccination (7), although there is some decay from the peak levels achieved after the second dose.”
From mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern (2021) · cites this paper as [7]
In the citing paper
“We previously showed that vaccination with mRNA-1273 elicited antibodies to SARS-CoV-2 WA1 in subjects aged 56 to 70 and 71 and older that are as potent (15) and durable (13) as those elicited in adults aged 18 to 55, with a slight decrease in potency for the oldest subjects in live-virus neutralization (13).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the citing paper
“In the pseudovirus neutralization assay, consistent with our previous study (13), 25% of sera neutralized WA1 after one dose (day 29).”
From Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (2021) · cites this paper as [13]
In the citing paper
“In clinical trials, two doses of mRNA-1273 also elicited durable antibody responses over a period of 6 months. Although antibody titres declined slightly over the duration of the study, high neutralizing ability was retained across all age groups205.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [205]
In the citing paper
“Several reports have measured the decay of neutralizing antibody responses raised by mRNA COVID-19 vaccines with a half-life of 69-173 days (Doria-Rose et al., 2021; Levin et al., 2021).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Doria-Rose et al., 2021
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Self-citationImmunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citationDurability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722
Self-citation
Flagged first, then by citations
1 of the 6 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 646
Chao, C.-H., Cheng, D., Huang, S., Chuang, Y., Yeh, T., & Wang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023943 · Cited by 11
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA
Liu, Y., Dai, L., Feng, X., Gao, R., Zhang, N., Wang, B., Han, J.-B., Zou, Q., Guo, X., Zhu, H., et al. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00054-z · Cited by 11
Sherman, A. C., Desjardins, M., & Baden, L. R. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.008 · Cited by 11
Liu, J., Bodnar, B. H., Padhiar, N. H., Khan, A. I., Meng, F., Saribas, S., Wang, P., Wang, X., McCluskey, E., Shah, S., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.644 · Cited by 11
Selvavinayagam, S. T., Yong, Y. K., Tan, H. Y., Zhang, Y., Subramanian, G., Rajeshkumar, M., Kalaivani, V., Jayapal, P., Narayanasamy, K., Ramesh, D., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.887974 · Cited by 11
Muñoz-Alía, M. Á., Nace, R. A., Balakrishnan, B., Zhang, L., Packiriswamy, N., Singh, G., Warang, P., Mena, I., Narjari, R., Vandergaast, R., et al. (2024) · mBio · doi:10.1128/mbio.02928-23 · Cited by 12
COVID-19 vaccination challenges: A mini-review
Afshar, Z. M., Barary, M., Hosseinzadeh, R., Karim, B., Ebrahimpour, S., Nazary, K., Sio, T. T. W., Sullman, M. J. M., Carson‐Chahhoud, K., Moudi, E., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2066425 · Cited by 14
Kumar, S., Jain, S., Wali, B., Zarnitsyna, V. I., Joshi, D., Ellis, M. L., Lai, L., Malik, A. A., McPherson, T., Godbole, S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu8067 · Cited by 12
Self-citationThe Perspective of Acquired Immunity to Combat against Infectious Diseases: An Overview
Islam, M. S., Chaudhuri, I., Mobin, M. A., Islam, M., Mahmud, M. S., KutubUddin, M., Kabir, K. M. A., & Kamrujjaman, M. (2021) · Health · doi:10.4236/health.2021.139077 · Cited by 10
Broseta, J. J., Rodríguez‐Espinosa, D., Bedini, J. L., Rodríguez, N., & Maduell, F. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab272 · Cited by 10
Stinca, S., Barnes, T. W., Peter, V., Meyers, W., Schulte-Pelkum, J., Filchtinski, D., Steller, L., Hauser, T., Manni, S., Gardiner, D., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259731 · Cited by 10
Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population
Weinberger, B. (2021) · Vaccines · doi:10.3390/vaccines9121435 · Cited by 11
Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
Mahrokhian, S. H., Tostanoski, L. H., Jacob-Dolan, C., Zahn, R. C., Wegmann, F., McMahan, K., Yu, J., Gebre, M. S., Bondzie, E. A., Wan, H., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00454-4 · Cited by 10
Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers
Assaid, N., Arich, S., Charoute, H., Akarid, K., Ezzikouri, S., Maaroufi, A., & Sarih, M. (2022) · Vaccines · doi:10.3390/vaccines10030465 · Cited by 12
Mochizuki, R. I., Takahashi, N., Ikenouchi, K., Shoda, W., Kuyama, T., & Takahashi, D. (2022) · CEN Case Reports · doi:10.1007/s13730-022-00702-5 · Cited by 10
Wang, F., Huang, B., Lv, H., Feng, L., Ren, W., Wang, X., Tang, L., Liu, Q., Wu, D., Zheng, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967051 · Cited by 10
Success of nano-vaccines against COVID-19: a transformation in nanomedicine
Sarangi, M. K., Padhi, S. K., Rath, G., Nanda, S. S., & Yi, D. K. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2148659 · Cited by 11
Dürrwald, R., Kolodziejek, J., Oh, D., Herzog, S., Liebermann, H., Osterrieder, N., & Nowotny, N. R. (2022) · Viruses · doi:10.3390/v14122706 · Cited by 10
Follmann, D. A., Janes, H., Chu, E., Jayashankar, L., Petropoulos, C. J., Serebryannyy, L., Carroll, R., Jean‐Baptiste, N., Narpala, S., Lin, B. C., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad069 · Cited by 12
Self-citationLiu, X., Park, H.-S., Matsuoka, Y., Santos, C. P., Yang, L., Luongo, C., Moore, I. N., Johnson, R. F., Garza, N. L., Zhang, P., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011057 · Cited by 10
Silva‐Moraes, V., Souquette, A. H., Sautto, G. A., Paciello, I., Antonelli, G., Andreano, E., Rappuoli, R., Teixeira‐Carvalho, A., & Ross, T. M. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300041 · Cited by 10
Kalnin, K. V., Plitnik, T., Kishko, M., Huang, D., Raillard, A., Piolat, J., Anosova, N. G., Tibbitts, T. J., DiNapoli, J. M., Karve, S., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.021 · Cited by 10
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic
Chen, P., Shi, X., He, W., Zhong, G., Tang, Y., Wang, H., & Zhang, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2040330 · Cited by 10
Panahi, Y., Einollahi, B., Beiraghdar, F., Darvishi, M., Fathi, S., Javanbakht, M., Shafiee, S., & Akhavan‐Sigari, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947602 · Cited by 10
Alhashimi, M., Sayedahmed, E. E., Elkashif, A., Chothe, S. K., Wang, W.-C., Murala, M. S. T., Gairola, V., Wakamatsu, N., Gontu, A., Ramasamy, S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01198-7 · Cited by 9
Immunological memory to vaccines
Crotty, S. (2026) · Immunity · doi:10.1016/j.immuni.2026.02.019 · Cited by 9
Study of humoral and cellular immunity in vaccinated with mRNA‐1273
Gutiérrez‐Bautista, J. F., López‐Nevot, M. Á., Gómez-Vicente, E., Quesada, T., Marín, E. M., Rodríguez, A. I. E., Rodríguez, A. I. E., Rodríguez‐Granger, J., Cobo, F., & Sampedro, A. (2022) · Apmis · doi:10.1111/apm.13215 · Cited by 10
de la Torre, J. C. G., Cáceres-DelAguila, J. A., Muro-Rojo, C., Cruz-Escurra, N. D. L., Corzo, C. A. C., Hueda-Zavaleta, M., Siles, D. A., & Benites-Zapata, V. A. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7050066 · Cited by 10
Ouyang, J., Zaongo, S. D., Harypursat, V., Li, X., Routy, J., & Chen, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.945448 · Cited by 11
COVID-19 Vaccination in Kidney Transplant Candidates and Recipients
Ponticelli, C., & Campise, M. (2022) · Vaccines · doi:10.3390/vaccines10111808 · Cited by 9
Choi, M. J., Heo, J. Y., Seo, Y. B., Yoon, Y. K., Sohn, J. W., Noh, J. Y., Cheong, H. J., Kim, W. J., Choi, J., Kim, H. J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035441 · Cited by 10
Torres, J., Ontañón, J., Ceña, V., Lozano, J., Requena, M. Á., Blas, J., Blas, J., Más, A., Más, A., & Solera, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1097747 · Cited by 9
Kim, M., Cheng, W. A., Congrave‐Wilson, Z., Ruiz, C. J. M., Turner, L. S., Mendieta, S., Jumarang, J., Valle, J. D., Lee, Y., Fabrizio, T. P., et al. (2023) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad107 · Cited by 9
Xue, P., Merikanto, I., Delale, E. A., Bjelajac, A. K., Yordanova, J., Chan, R. N. Y., Korman, M., Mota-Rolim, S. A., Landtblom, A., Matsui, K., et al. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01556-w · Cited by 9
Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants
Chatterjee, B., & Thakur, S. S. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.1997601 · Cited by 9
Sander, I., Kespohl, S., Zahradnik, E., Göcke, P., Hosbach, I., Herrmann, B. L., Brüning, T., & Raulf, M. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1369 · Cited by 9
Stem cell therapy for COVID-19 pneumonia
Kebria, M. M., Milan, P. B., Peyravian, N., Kiani, J., Khatibi, S., & Mozafari, M. (2022) · Molecular Biomedicine · doi:10.1186/s43556-021-00067-8 · Cited by 10
Salehi, M., Hosseini, H., Jamshidi, H., Jalili, H., Tabarsi, P., Mohraz, M., Karimi, H., Lotfinia, M., Aalizadeh, R., Mohammadi, M., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.030 · Cited by 9
Congrave‐Wilson, Z., Cheng, W. A., Lee, Y., Perez, S. E., Turner, L. S., Ruiz, C. J. M., Mendieta, S., Skura, A., Jumarang, J., Valle, J. D., et al. (2022) · Vaccines · doi:10.3390/vaccines10050813 · Cited by 10
Sakamoto, A., Yoshimura, M., Itoh, R., Ozuru, R., Ishii, K., Sechi, Y., Nabeshima, S., & Hiromatsu, K. (2022) · Vaccines · doi:10.3390/vaccines10060830 · Cited by 9
Leav, B. A., Straus, W. L., White, P., Leav, A., Gaines, T., Maggiacomo, G., Kim, D., Smith, E. R., Gurwith, M., & Chen, R. T. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.005 · Cited by 9
Self-citationZember, S., Bodulić, K., Balent, N. C., Mikulić, R., Markotić, A., & Rode, O. Đ. (2022) · Vaccines · doi:10.3390/vaccines10111813 · Cited by 10
Grassi, T., Lobreglio, G., Panìco, A., Rosato, C., Zizza, A., Lazzari, R., Chicone, M., Indino, F., & Bagordo, F. (2022) · Vaccines · doi:10.3390/vaccines10111948 · Cited by 10
Zheng, Y., Pan, J., Jin, M., Wang, J., Tung, T., Chen, S., Bi, X., Zhou, K., Chen, M., Wang, D., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110151 · Cited by 9
Impact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States
Fang, F., Clemens, J. D., Zhang, Z., & Brewer, T. F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301830 · Cited by 9
COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants
Stefanelli, P., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10060905 · Cited by 10
Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA VaccinationsPreprint
Bliden, K. P., Liu, T., Sreedhar, D., Kost, J., Hsiung, J., Zhao, S., Shan, D., Usman, A., Walia, N., Cho, A., et al. (2021) · medRxiv · doi:10.1101/2021.06.28.21259338 · Cited by 10
Cvetković-Vega, A., Urrunaga‐Pastor, D., Soto-Becerra, P., Figueroa-Montes, L. E., Bolívar, L. F., Alvizuri-Pastor, S. E., Oyanguren-Miranda, M., Vera, I. M. N., Carrillo-Ramos, E., Soto, A. A. I. S., et al. (2022) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2022.102514 · Cited by 8
Kohmer, N., Stein, S., Schenk, B., Grikscheit, K., Metzler, M., Rabenau, H. F., Widera, M., Herrmann, E. M., Wicker, S., & Ciesek, S. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.034 · Cited by 8
Ma, Y., Huang, Y., & Xu, G. (2023) · QJM · doi:10.1093/qjmed/hcac287 · Cited by 8
Joshi, K., Rumpler, É., Kennedy‐Shaffer, L., Bosan, R., & Lipsitch, M. (2023) · Vaccine · doi:10.1016/j.vaccine.2022.12.053 · Cited by 10
Ciccone, E. J., Zhu, D., Gunderson, A. K., Hawke, S., Ajeen, R., Lodge, E. K., Shook‐Sa, B. E., Abernathy, H., Garrett, H. E., King, E., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae009 · Cited by 9
Fisher, J. S., Adán‐Barrientos, I., Kumar, N., & Lancaster, J. N. (2024) · Aging Cell · doi:10.1111/acel.14140 · Cited by 8
Figueroa, A. L., Ali, K., Berman, G., Zhou, H., Deng, W., Xu, W., Lussier, S. J., Girard, B., Dutko, F. J., Slobod, K., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102720 · Cited by 8
Chen, Z., Xie, F., Zhang, H., Dong, L., Zhang, S., Zhang, M., Li, J., Xie, J., Zhang, L., Yang, X., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1478627 · Cited by 10
A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy
Palladino, R., Ceriotti, D., Ambrosi, D. D., Vito, M. D., Farsoni, M., Seminara, G., & Barone‐Adesi, F. (2021) · Vaccines · doi:10.3390/vaccines9060618 · Cited by 8
Corrao, G., Bertolaso, G., Pavesi, G., & Moratti, L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031073 · Cited by 8
Padhiar, N. H., Liu, J., Wang, X., Wang, X., Bodnar, B. H., Khan, S., Wang, P., Khan, A. I., Luo, J. J., Hu, W., et al. (2022) · Vaccines · doi:10.3390/vaccines10060858 · Cited by 8
Meng, L. M., Murthy, N. C., Murthy, B. P., Zell, E. R., Saelee, R., Irving, M., Fast, H. E., Roman, P. C., Schiller, A., Shaw, L., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2808.220557 · Cited by 9
The influence of SARS‐CoV ‐2 vaccination on post‐operative outcomes in microsurgery patients
Taghioff, S. M., Slavin, B. R., Narasimman, M., Samaha, G. J., Samaha, M. J., Holton, T., & Singh, D. P. (2022) · Microsurgery · doi:10.1002/micr.30940 · Cited by 8
Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS
Forte, E., Soye, B. J. D., Melani, R. D., Hollas, M. A. R., Kafader, J. O., Sha, B. E., Schneider, J. R., & Kelleher, N. L. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00514 · Cited by 8
Xie, H., Wen, X., Li, J., Chen, W., Chen, M., Zhang, L., Lv, M., Zhou, S., Bai, S., Zhao, W., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.068 · Cited by 8
Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021–July 2021)
Kanji, J. N., Nguyen, L. T., Plitt, S. S., Charlton, C. L., Fenton, J., Braun, S., Marohn, C., Lau, C. K. Y., Svenson, L. W., Hinshaw, D., et al. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2022.2080250 · Cited by 8
Wang, T., Li, C., Li, H., & Li, Z. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057281 · Cited by 8
A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadthPreprint
Iketani, S., Liu, L., Nair, M. S., Mohri, H., Wang, M., Huang, Y., & Ho, D. D. (2021) · medRxiv · doi:10.1101/2021.08.11.21261670 · Cited by 8
Severe Acute Respiratory Syndrome Coronavirus‐2
Slev, P. R. (2024) · Wiley eBooks · doi:10.1002/9781683674023.ch54 · Cited by 8
Dittadi, R., Seguso, M., Bertoli, I., Afshar, H., & Carraro, P. (2021) · Diagnostics · doi:10.3390/diagnostics11091709 · Cited by 7
Παπαδοπούλου, Α., Stavridou, F., Giannaki, M., Paschoudi, K., Chatzopoulou, F. M., Gavriilaki, E., Georgolopoulos, G., Anagnostopoulos, Α., & Yannaki, E. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09863 · Cited by 7
Optimal COVID-19 testing strategy on limited resources
Tatsuki, O., Naoki, H., & Igarashi, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281319 · Cited by 7
A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA
Rachman, A., Iriani, A., Sukrisman, L., Rajabto, W., Mulansari, N. A., Lubis, A. M., Cahyanur, R., Prasetyawaty, F., Priantono, D., Rumondor, B. B., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281907 · Cited by 8
Ng, E., Choi, C., & Wang, S. X. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133773 · Cited by 7
Ishikawa, K., Nascimento, M., Asano, M., Hirata, H., Itoh, Y., Kelly, E. J., Matsui, A., Olsson, U., Shoemaker, K., & Green, J. A. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.015 · Cited by 7
Fedele, G., Schiavoni, I., Trentini, F., Leone, P., Olivetta, E., Fallucca, A., Fiore, S., Martino, A. D., Abrignani, S., Baldo, V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1272119 · Cited by 7
Smirnova, A., & Baroonian, M. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.12.001 · Cited by 7
Santos-Rebouças, C. B., Ferreira, C. D. S., Nogueira, J. D. S., Brustolini, O. J. B., de Almeida, L. G. P., Gerber, A. L., Guimarães, A. P. D. C., Piergiorge, R. M., Struchiner, C. J., Pôrto, L. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59259-1 · Cited by 7
Exposure proximal immune correlates analysis
Huang, Y., & Follmann, D. A. (2024) · Biostatistics · doi:10.1093/biostatistics/kxae031 · Cited by 7
Rojas-Jiménez, G., Solano, D., Segura, Á., Sánchez, A., Chaves-Araya, S., Herrera, M., Vargas, M., Cerdas, M., Calvo, G., Alfaro, J., et al. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2021.772275 · Cited by 7
Klingel, H., Lauen, M., Krüttgen, A., Imöhl, M., & Kleines, M. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.1.121 · Cited by 7
Polvere, I., Parrella, A., Zerillo, L., Voccola, S., Cardinale, G., D’Andrea, S., Madera, J. R., Stilo, R., Vito, P., & Zotti, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.833085 · Cited by 7
Li, J., Hui, A., Zhang, X., Ge, L., Qiu, Y., Tang, R., Ye, H., Wang, X., Lin, M., Zhu, Z., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02206-1 · Cited by 7
Gil-Manso, S., Carbonell, D., Pérez-Fernández, V. A., López-Esteban, R., Alonso, R., Muñóz, P., Ochando, J., Sánchez-Arcilla, I., Bellón, J. M., Correa‐Rocha, R., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071676 · Cited by 7
El-Menyar, A. A., Khan, N. A., Mekkodathil, A. A., Rizoli, S. B., Consunji, R. J., Elmenyar, E., Galwankar, S. C., & Al-Thani, H. A. S. (2022) · Medicine · doi:10.1097/md.0000000000030609 · Cited by 7
García‐Pérez, J., Bermejo, M., Ramírez‐García, A., Tarazona, E. D. L. T., Cascajero, A., de la Osa, M. C., Jiménez, P., Gómez, M. A., Calonge, E., Sancho‐López, A., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28679 · Cited by 7
Doherty, J., O’Morain, N. R., Stack, R., Tosetto, M., Inzitiari, R., O’Reilly, S. R., Gu, L., Sheridan, J., Cullen, G. J., Dermott, E. M., et al. (2023) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjad065 · Cited by 8
Meejun, T., Srisurapanont, K., Manothummetha, K., Thongkam, A., Mejun, N., Chuleerarux, N., Sanguankeo, A., Phongkhun, K., Leksuwankun, S., Thanakitcharu, J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010349 · Cited by 7
Bar‐Or, A., Aburashed, R. A., Chinea, A. R., Hendin, B. A., Lucassen, E. B., Meng, X., Stankiewicz, J. M., Tullman, M. J., & Cross, A. H. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104967 · Cited by 7
Asamoah-Boaheng, M., Grunau, B. E., Haig, S., Karim, M. E., Kirkham, T. L., Lavoie, P. M., Sediqi, S., Drews, S. J., O’Brien, S. F., Barakauskas, V., et al. (2023) · Access Microbiology · doi:10.1099/acmi.0.000678.v3 · Cited by 6
Cervantes‐Torres, J. B., Cabello-Gutiérrez, C., Ayón‐Núñez, D. A., Soldevila, G., Olguín‐Alor, R., Díaz, G., Acero, G., Segura‐Velázquez, R. A., Huerta, L., Gracia‐Mora, I., et al. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12927-0 · Cited by 7
COVID vaccines and breastfeeding: what the data say
Hall, S. (2021) · Nature · doi:10.1038/d41586-021-01680-x · Cited by 7
Tsipotis, E., Frey, S. M., Connolly, C. M., Werbel, W. A., Chowdhury, R., Dudley-Brown, S. L., Melia, J., Parian, A. M., Truta, B., Yu, H. M., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001668 · Cited by 7
Eliakim‐Raz, N., Stemmer, A., Weissman, Y. L., Ness, A., Awwad, M., Ghantous, N., Noam Erez, A., Bareket‐Samish, A., Levy‐Barda, A., Ben‐Zvi, H., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061584 · Cited by 7
Herd immunity: challenges and the way forward in Korea
Oh, J., Kim, S., Ryu, B., Shin, M., & Kim, B. I. (2021) · Epidemiology and Health · doi:10.4178/epih.e2021054 · Cited by 7
Mastroianni, F., Guida, P., Bellanova, G., Nicolò, E. V. D., Righetti, G., Formoso, M., & Celani, F. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100175 · Cited by 6
Real-World COVID-19 Vaccine Protection Rates against Infection in the Delta and Omicron Eras
Zhu, Y., Gu, J., Qiu, Y., & Chen, S. X. (2023) · Research · doi:10.34133/research.0099 · Cited by 6
Future prospects in mRNA vaccine development
Mbatha, L. S., Akinyelu, J., Maiyo, F., & Kudanga, T. (2023) · Biomedical Materials · doi:10.1088/1748-605x/aceceb · Cited by 7
mRNA Vaccines Beyond COVID-19: Emerging Therapeutic Frontiers
Mohammad, W. T., & Sayeh, A. M. A. (2024) · Trends in Pharmaceutical Biotechnology · doi:10.57238/tpb.2024.153196.1020 · Cited by 6
Prasad, R. M., Srivastava, S., Wang, E., Liu, J. Z., Gami, R., AbdelGadir, A., Sharma, A., Rayamajhi, S., & Tikaria, R. (2021) · The Permanente Journal · doi:10.7812/tpp/21.035 · Cited by 6
Poehlein, E., Rane, M. S., Frogel, D., Kulkarni, S., Gainus, C., Profeta, A., Robertson, M. M., & Nash, D. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115720 · Cited by 6
Wolszczak-Biedrzycka, B., Bieńkowska, A., Zaborowska, J. E., Smolińska-Fijołek, E., Biedrzycki, G., & Dorf, J. (2022) · Vaccines · doi:10.3390/vaccines10050741 · Cited by 6
Lagousi, T., Routsias, J. G., Mavrouli, M. D., Papadatou, I., Geropeppa, M., & Spoulou, V. I. (2022) · Vaccines · doi:10.3390/vaccines10081210 · Cited by 6
Metadata
- Authors
- Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., O’Dell, S., Schmidt, S. D., Widge, A. T., Edara, V.-V., Anderson, E. J., Lai, L., Floyd, K., Rouphael, N. G., Zarnitsyna, V., Roberts, P. C., Makhene, M., Buchanan, W., Luke, C. J., Beigel, J. H., Jackson, L. A., Neuzil, K. M., Bennett, H., Leav, B., Albert, J., & Kunwar, P.
- Affiliations
- National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD
- Emory University (US)
- Emmes (United States) (US)
- National Institutes of Health (US)
- NIAID, Bethesda, MD
- Kaiser Permanente Washington Health Research Institute (US)
- University of Maryland, Baltimore (US)
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Suthar, Mehul S.
- ORCID
- Doria-Rose, Nicole
- Suthar, Mehul S.
- Makowski, Mat
- O’Connell, Sarah
- McDermott, Adrian B.
- Ledgerwood, Julie E.
- Mascola, John R.
- Graham, Barney S.
- Lin, Bob C.
- Schmidt, Stephen D.
- Widge, Alicia T.
- Edara, Venkata-Viswanadh
- Anderson, Evan J.
- Lai, Lilin
- Floyd, Katharine
- Rouphael, Nadine G.
- Zarnitsyna, Veronika
- Roberts, Paul C.
- Beigel, John H.
- Jackson, Lisa A.
- Neuzil, Kathleen M.
- Bennett, Hamilton
- Leav, Brett
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-10
- Volume
- 384
- Issue
- 23
- Pages
- 2259-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8524784
- OpenAlex
- W3142193311
- Cited by
- 673
- References
- 6
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 40 · 2023: 104 · 2022: 287 · 2021: 199
- FWCI
- 49.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Covid-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine
- North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill
- North Carolina Coronavirus Relief Fund
- Coalition for Epidemic Preparedness Innovations
- Georgia Research Alliance
- National Institute of Allergy and Infectious Diseases (AI149644, HHSN272201500002C, P51 OD011132, UM1AI148373, UM1AI148576, UM1AI148684, UM1Al148684-01S1)
- National Center for Advancing Translational Sciences (UL1 TR002243)
- Dolly Parton COVID-19 Research Fund
- Emory Executive Vice President for Health Affairs Synergy Fund award
- Center for Childhood Infections and Vaccines
- Children’s Healthcare of Atlanta
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccination, antibody persistence, humoral immune response, Moderna vaccine, booster vaccination, SARS-CoV-2 antibodies
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adult, Aged, Antibodies, Viral, Half-Life, Humans, Middle Aged, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
